![]() |
contents | america | ||||
| Drug Discovery & Development of Innovative Therapeutics Congress ![]() Bolen has confirmed academia speakers including: Kenneth C. Anderson, M.D., Dana Farber Cancer Institute, Harvard Medical School; Bruce E. Johnson, M.D., Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital; Mark A. Israel, M.D., Dartmouth Medical School; Neal Rosen, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center; Massimo Loda, M.D., Dana Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School Companies also giving technical conference presentations in this cancer track include Alnylam Pharmaceuticals, Amgen, Inc., ARIAD Pharmaceuticals Inc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company, Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals, Inc, Merck Research Laboratories, Novartis Institutes for BioMedical Research, OncoMed Pharmaceuticals Inc, The Johnson & Johnson Family of Companies. Additional conference sessions at Drug Discovery & Development of Innovative Therapeutics conference include Cardio-Metabolic Disease Drug Discovery and Development; Translational Medicine/Research; Transforming Technologies; Anti-Infective Drug Discovery and Development; Neurodegenerative Disease Drug Discovery and Development; Inflammation in Drug Discovery and Development; Orphan Diseases: Fast-Tracking Orphan Drugs and Scientific Advances; The Next Generation of Therapeutics: Emerging Biologics, Stem Cells and RNAi. The event provides a meeting place for attendees from around the world to network, find business and scientific partners and to discuss scientific advances, R&D strategies, business alliances and informatics solutions in drug discovery and development. write your comments about the article :: © 2008 Exhibition News :: home page |